Skip Navigation

Shuji Ogino, MD, PhD, MS

Oncologic Pathology

Make an Appointment


  • Professor of Pathology, Harvard Medical School
  • Professor, Department of Epidemiology, Harvard T.H. Chan School of Public Health
  • Chief, Program of Molecular Pathological Epidemiology, Brigham and Women’s Hospital
  • Associate Member, Broad Institute of MIT and Harvard


Clinical Interests

  • Molecular diagnostics

Contact Information

  • Appointments877-332-4294
  • Office Phone Number617-632-1985
  • Fax617-582-8558


Dr. Ogino received his MD in 1993 and his PhD in 2001 from the University of Tokyo, Japan. He completed his residency in anatomic pathology and clinical pathology at Case Western Reserve University and University Hospitals Case Medical Center in 1999, and a molecular pathology fellowship in 2000 at the University of Pennsylvania. He joined Dana-Farber Cancer Institute as an Instructor in 2001. In 2015, Dr. Ogino was promoted to Professor of Pathology at Dana-Farber Cancer Institute, Brigham and Women’s Hospital (BWH), and Harvard Medical School; and Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. In 2016, Dr. Ogino became the first Chief of the Division of Molecular Pathological Epidemiology (MPE) at BWH. Dr. Ogino has been serving as the Chairperson for the International Molecular Pathological Epidemiology (MPE) Meeting Series since 2013. Dr. Ogino has received a number of awards and honors, particularly in recognition of his pioneering effort of establishing the interdisciplinary and integrative field of MPE. These recognitions include the Ramzi Cotran Young Investigator Award from the United States and Canadian Academy of Pathology (USCAP) in 2011; Executive Officer’s Award (2004) and Meritorious Service Award (2012) from the Association for Molecular Pathology (AMP); Elected Membership of American Society for Clinical Investigation (since 2014); recognition as the Most Influential Scientific Minds (2014), and High Cited Researcher (2015) by Thomson Reuters; and a 7-year grant, NCI R35 Outstanding Investigator Award (2015-2022) from the National Institute of Health.

Board Certification:

  • Anatomic Pathology and Clinical Pathology, 2000
  • Molecular Genetic Pathology, 2003


  • University of Pennsylvania, Molecular Pathology


  • Case Western Reserve University, Anatomic Pathology and Clinical Pathology

Medical School:

  • Harvard School of Public Health (MS in Epidemiology)
  • University of Tokyo
  • University of Tokyo Graduate School of Medicine (PhD)

Recent Awards:

  • Highly Cited Researcher (Clarivate Analytics), 2017
  • Highly Cited Researcher (Clarivate Analytics), 2016
  • Highly Cited Researcher (Thomson Reuters), 2015
  • Recipient of R35 Outstanding Investigator Award from National Cancer Institute, 2015 to present
  • Elected Membership of American Society for Clinical Investigation (ASCI), 2014
  • The Most Influential Scientific Minds (Thomson Reuters), 2014
  • Meritorious Service Award, from Association for Molecular Pathology (AMP) October 2012
  • Ramzi Cotran Young Investigator Award, from United States and Canadian Academy of Pathology (USCAP) March 2011


The Molecular Pathological Epidemiology Laboratory (The MPE Laboratory)

The relationship between exposures and tumor molecular changes has been examined (eg, smoking -> KRAS mutation), under the umbrella of "molecular epidemiology".  However, this type of analysis needs a consideration of disease heterogeneity (eg, KRAS mutation present vs. absent), which necessitates a paradigm shift from conventional epidemiology, which is based on the premise that individuals with a given disease (by name) are homogeneous and can be lumped together to analyze the associations with exposures.

Considering this paradigm shift, “Molecular Pathological Epidemiology (MPE)” (or Molecular Pathologic Epidemiology) has been coined for integrative science to analyze inherent disease heterogeneity in epidemiology research (Ogino et al. JNCI 2010; Gut 2011; Nat Rev Clin Oncol 2011).  The power and promise of MPE has been well attested by our recent study (Liao et al. NEJM 2012) which discovered an interactive effect of aspirin use and colorectal cancer PIK3CA mutation.  MPE encompasses ALL HUMAN DISEASES (Ogino et al. Mod Pathol 2013).  MPE is based on the "Unique Tumor Principle" (Ogino et al. Expert Rev Mol Diagn 2012) and more broadly, the “Unique Disease Principle” (Ogino et al. Mod Pathol 2013).  MPE design can be used as the next step of genome-wide association study (“GWAS-MPE Approach”; Ogino et al. Gut 2011; Garcia-Albeniz et al. Carcinogenesis 2013).  Other new concepts related to MPE include "Colorectal Continuum Paradigm / Theory / Hypothesis" (Yamauchi, et al. Gut 2012), which underscores the importance of interplay of gut microbiota, microbiome, host factors and carcinogenesis. 

We have been utilizing two large U.S. nationwide prospective cohort studies, the Nurses’ Health Study, and the Health Professionals Follow-up Study, as well as CALGB trials.  Our discoveries by the MPE approach include (to mention just several); influence of the tumor microenvironment on tumor phenotype (Straussman et al. Nature 2012); YAP1 in colorectal cancer (Barry et al. Nature 2013); interactions between aspirin use and tumor PTGS2 (cyclooxygenase-2) expression (Chan et al. NEJM 2007; JAMA 2009); interactions between obesity (host energetics) and tumor FASN expression (Ogino et al. J Clin Oncol 2008; Kuchiba et al. JNCI 2012); interactions between host energetics and tumor CTNNB1 (b-catenin) (Morikawa et al. JAMA 2011; Cancer Res 2013); LINE-1 hypomethylation and colon cancer aggression and family history (Ogino et al. JNCI 2008; JNCI 2013).

(For full description, please visit )


Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 422B
Boston, MA 02215
Get Directions

Brigham and Women's Hospital
75 Francis Street
Boston, MA 02215
Get Directions